Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5203_Библиотеки_им_академика_М_И_Перельмана.pdf
290
51. Alghamdi SA.Hypnic jerks, major depressive disorder, and antidepressant use: a possible
relationship. Cureus. 2023;15(10):e47436.
52. Brigo F, Igwe SC, Bragazzi NL, etal. Clonazepam monotherapy for treating people with
newly diagnosed epilepsy. Cochrane Database Syst Rev. 2022;2(2):CD013028.
53. Han S, Lim JH, Bang J, etal. Use of a combination of N-acetylcysteine and clonazepam to treat
burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;132(5):532–8.
54. Gautam M, Kaur M, Sivananthan M.Parotid gland enlargement associated with clonazepam:
a case report. J Acad Consult Liaison Psychiatry. 2021;62(6):657–8.
55. Lutz EW, Hines C.Recurrent clonazepam withdrawal delirium in a postoperative neurosurgical patient: a case report. BMJ Case Rep. 2021;14(6):e240804.
56. Muramatsu K, Ujiie H, Natsuga K, etal. Lichenoid drug eruption caused by clonazepam. J
Eur Acad Dermatol Venereol. 2017;31(2):e117–e8.
57. Seynejad B, Ozkan SA, Jouyban A.Ultrasound-assisted electromembrane extraction of
clonazepam from plasma and determination using capillary electrophoresis. J Chromatogr B
Analyt Technol Biomed Life Sci. 2021;1181:122928.
58. An J, Wang X, Li Y, etal. Polystyrene nanobers as an effective sorbent for the adsorption of
clonazepam: kinetic and thermodynamic studies. RSC Adv. 2022;12(6):3394–401.
59. Piwowarczyk-Nowak A, Pałasz A, Bogus K, et al. Modulatory effect of long-term treatment with escitalopram and clonazepam on the expression of anxiety-related neuropeptides: neuromedin U, neuropeptide S and their receptors in the rat brain. Mol Biol Rep.
2022;49(9):9041–9.
60. Chuang SH, Westenbroek RE, Stella N, etal. Combined antiseizure efcacy of cannabidiol and clonazepam in a conditional mouse model of Dravet syndrome. J Exp Neurol.
2021;2(2):81–5.
61. da Silva LGR, da Silva Pinto AW, de Queiroz WE, etal. Deprescribing clonazepam in primary care older patients: a feasibility study. Int J Clin Pharm. 2022;44(2):489–98.
62. Byun JI, Shin YY, Seong YA, et al. Comparative efcacy of prolonged-release melatonin
versus clonazepam for isolated rapid eye movement sleep behavior disorder. Sleep Breath.
2023;27(1):309–18.
63. French JF, Rapoport RM, Matlib MA.Possible mechanism of benzodiazepine-induced relaxation of vascular smooth muscle. J Cardiovasc Pharmacol. 1989;14(3):405–11.
64. Dell’Isola GB, Vinti V, Fattorusso A, etal. The broad clinical spectrum of epilepsies associated with protocadherin 19 gene mutation. Front Neurol. 2021;12:780053.
65. Sorel L. [Experimental antipileptic action and clinical action of zarontin]. Acta Neurol
Psychiatr Belg. 1960;60:551–9.
66. Lossius HM.Experience with a new anti-convulsant of the succimide group, zarontin. Acta
Psychiatr Scand Suppl. 1961;36(150):200–8.
67. Prot J, Saper J, Stroinska B. [Zarontin therapy of petit mal epilepsy resistant to anticonvulsants]. Neurol Neurochir Psychiatr Pol. 1963;13:487–90.
68. Dooley JM, Cameld PR, Cameld CS, etal. Once-daily ethosuximide in the treatment of
absence epilepsy. Pediatr Neurol. 1990;6(1):38–9.
69. Terzioğlu B, Aypak C, Onat FY, etal. The effects of ethosuximide on amino acids in genetic
absence epilepsy rat model. J Pharmacol Sci. 2006;100(3):227–33.
70. Gülhan Aker R, Tezcan K, Carçak N, etal. Localized cortical injections of ethosuximide
suppress spike-and-wave activity and reduce the resistance to kindling in genetic absence
epilepsy rats (GAERS). Epilepsy Res. 2010;89(1):7–16.
71. Buschhoff AS, Scherliess R, de Mooij-van Malsen JG, etal. Intrathecal application of ethosuximide is highly efcient in suppressing seizures in a genetic model of absence epilepsy.
Epilepsy Res. 2022;184:106967.
72. Ascoli M, Mastroianni G, Gasparini S, etal. Diagnostic and therapeutic approach to drugresistant juvenile myoclonic epilepsy. Expert Rev Neurother. 2021;21(11):1265–73.
73. Samanta D.Pharmacotherapeutic management of seizures in patients with Angleman syndrome. Expert Opin Pharmacother. 2022;23(13):1511–22.
W. Jing et al.
2 Antiseizure Medications
74. Shawahna R, Zaid L. Concentrations of antiseizure medications in breast milk of lactating women with epilepsy: a systematic review with qualitative synthesis. Seizure.
2022;98:57–70.
75. Brigo F, Igwe SC, Lattanzi S.Ethosuximide, sodium valproate or lamotrigine for absence
seizures in children and adolescents. Cochrane Database Syst Rev. 2021;1(1):CD003032.
76. Rinaldi VE, Di Cara G, Mencaroni E, etal. Therapeutic options for childhood absence epilepsy. Pediatr Rep. 2021;13(4):658–67.
77. Mostacci B, Ranzato F, Giuliano L, etal. Alternatives to valproate in girls and women of
childbearing potential with idiopathic generalized epilepsies: state of the art and guidance for
the clinician proposed by the Epilepsy and Gender Commission of the Italian League Against
Epilepsy (LICE). Seizure. 2021;85:26–38.
78. Besag FMC, Vasey MJ.Neurocognitive effects of antiseizure medications in children and
adolescents with epilepsy. Paediatr Drugs. 2021;23(3):253–86.
79. Strzelczyk A, Schubert-Bast S.Psychobehavioural and cognitive adverse events of antiseizure medications for the treatment of developmental and epileptic encephalopathies. CNS
Drugs. 2022;36(10):1079–111.
80. Buraniqi E, Dabaja H, Wirrell EC.Impact of antiseizure medications on appetite and weight
in children. Paediatr Drugs. 2022;24(4):335–63.
81. Sáenz-Farret M, Tijssen MAJ, Eliashiv D, etal. Antiseizure drugs and movement disorders.
CNS Drugs. 2022;36(8):859–76.
82. Shang H, Glaun M, Ongkasuwan J.Ethosuximide induced macroglossia and oropharyngeal
edema. Int J Pediatr Otorhinolaryngol. 2021;140:110498.
83. Nagu P, Sharma V, Behl T, etal. Molecular insights to the Wnt signaling during Alzheimer’s
disorder: a potential target for therapeutic interventions. J Mol Neurosci. 2022;72(4):679–90.
84. Tatum S, Smith ZZ, Taylor JA, etal. Sensitivity of unilateral- versus bilateral-onset spikewave discharges to ethosuximide and carbamazepine in the uid percussion injury rat model
of traumatic brain injury. J Neurophysiol. 2021;125(6):2166–77.
85. El-Haggar SM, Hegazy SK, Abd-Elsalam SM, Bahaa MM, etal. Open-label pilot study of
ethosuximide as adjunctive therapy for relieving abdominal pain related to Irritable Bowel
Syndrome. J Clin Pharm Ther. 2022;47(3):306–12.
86. Gadotti VM, Zamponi GW.Ethosuximide inhibits acute histamine- and chloroquine-induced
scratching behavior in mice. Mol Brain. 2021;14(1):46.
87. Porter RJ, Penry JK.Phenobarbital: biopharmacology. Adv Neurol. 1980;27:493–500.
88. Pigatto PD, Morelli M, Polenghi MM, et al. Phenobarbital-induced allergic dermatitis.
Contact Derm. 1987;16(5):279.
89. Crawford TO, Mitchell WG.Phenobarbital for status. Neurology. 1989;39(4):609.
90. Lindberg MC, Cunningham A, Lindberg NH.Acute phenobarbital intoxication. South Med
J. 1992;85(8):803–7.
91. Brodie MJ, Kwan P.Current position of phenobarbital in epilepsy and its future. Epilepsia.
2012;53(Suppl 8):40–6.
92. Pacici GM.Clinical pharmacology of phenobarbital in neonates: effects, metabolism and
pharmacokinetics. Curr Pediatr Rev. 2016;12(1):48–54.
93. Hofmeister B, von Stülpnagel C, Betzler C, etal. Epilepsy in Nicolaides-Baraitser syndrome:
review of literature and report of 25 patients focusing on treatment aspects. Neuropediatrics.
2021;52(2):109–22.
94. Su Y, Huang H, Jiang M, et al. Phenobarbital versus valproate for generalized convulsive
status epilepticus in adults (2): a multicenter prospective randomized controlled trial in China
(China 2-P vs. V). Epilepsy Res. 2021;177:106755.
95. Jain P, Aneja S, Cunningham J, etal. Treatment of benzodiazepine-resistant status epilepticus: systematic review and network meta-analyses. Seizure. 2022;102:74–82.
96. Liu G, Wang Y, Tian F, et al. Long-term follow-up of phenobarbital versus valproate for
generalized convulsive status epilepticus in adults: a randomized clinical trial. Epilepsy Res.
2023;195:107187.
291
292
97. Jindal A, Angurana SK, Suthar R, etal. Effect of early withdrawal of phenobarbitone on the
recurrence of neonatal seizures: an open-label randomized controlled trial. Epilepsy Behav.
2021;117:107875.
98. Ziobro JM, Eschbach K, Shellhaas RA. Novel therapeutics for neonatal seizures.
Neurotherapeutics. 2021;18(3):1564–81.
99. Dizon MLV, Rao R, Hamrick SE, etal. Practice variation in anti-epileptic drug use for neonatal hypoxic-ischemic encephalopathy among regional NICUs. BMC Pediatr. 2019;19(1):67.
100. Lin YC, Lai YC, Chou P, etal. How can an Na(+) channel inhibitor ameliorate seizures in
Lennox-Gastaut syndrome? Ann Neurol. 2021;89(6):1099–113.
101. Kaplan YC, Demir O. Use of phenytoin, phenobarbital carbamazepine, levetiracetam
lamotrigine and valproate in pregnancy and breastfeeding: risk of major malformations, dosedependency, monotherapy vs polytherapy, pharmacokinetics and clinical implications. Curr
Neuropharmacol. 2021;19(11):1805–24.
102. Tomson T, Battino D, Bonizzoni E, etal. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–8.
103. Bromley R, Adab N, Bluett-Duncan M, etal. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev.
2023;8(8):CD010224.
104. Zuppa AA, Carducci C, Scorrano A, et al. Infants born to mothers under phenobarbital
treatment: correlation between serum levels and clinical features of neonates. Eur J Obstet
Gynecol Reprod Biol. 2011;159(1):53–6.
105. Verstegen RHJ, Anderson PO, Ito S. Infant drug exposure via breast milk. Br J Clin
Pharmacol. 2022;88(10):4311–27.
106. Sharma D, Hussain AM, Sharma SS.Efcacy of levetiracetam in neonatal seizures: a systematic review. J Matern Fetal Neonatal Med. 2022;35(20):3923–30.
107. Gyandeep G, Behura SS, Sahu SK, etal. Comparison between phenobarbitone and levetiracetam as the initial anticonvulsant in preterm neonatal seizures– a pilot randomized control
trial in developing country setup. Eur J Pediatr. 2023;182(5):2133–8.
108. Soul JS, Bergin AM, Stopp C, etal. A pilot randomized, controlled, double-blind trial of
bumetanide to treat neonatal seizures. Ann Neurol. 2021;89(2):327–40.
109. Variane GFT, Dahlen A, Pietrobom RFR, etal. Remote monitoring for seizures during therapeutic hypothermia in neonates with hypoxic-ischemic encephalopathy. JAMA Netw Open.
2023;6(11):e2343429.
110. Kumar J, Meena J, Yadav J, et al. Efcacy and safety of phenobarbitone as rst-line
treatment for neonatal seizure: a systematic review and meta-analysis. J Trop Pediatr.
2021;67(1):fmab008.
111. Liguori C, Toledo M, Kothare S. Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: a literature review. Sleep Med Rev.
2021;60:101559.
112. Johne M, Käufer C, Römermann K, etal. A combination of phenobarbital and the bumetanide
derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia. Epilepsia. 2021;62(6):1460–71.
113. Johne M, Römermann K, Hampel P, etal. Phenobarbital and midazolam suppress neonatal
seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective.
Epilepsia. 2021;62(4):920–34.
114. Marsh O, Corsini G, Van Dijk J, etal. Prevalence and clinical characteristics of phenobarbitoneassociated adverse effects in epileptic cats. J Feline Med Surg. 2021;23(2):59–66.
115. Liu J, Wang LN. Treatment of epilepsy for people with Alzheimer’s disease. Cochrane
Database Syst Rev. 2021;5(5):CD011922.
116. Karaźniewicz-Łada M, Główka AK, Mikulska AA, etal. Pharmacokinetic drug-drug interactions among antiepileptic drugs, including CBD, drugs used to treat COVID-19 and nutrients.
Int J Mol Sci. 2021;22(17):9582.
W. Jing et al.
2 Antiseizure Medications
117. Peters J, Vijiaratnam N, Angus-Leppan H.Tics induced by antiepileptic drugs: a pragmatic
review. J Neurol. 2021;268(1):321–36.
118. Shamabadi A, Karimi H, Arabzadeh Bahri R, et al. Emerging drugs for the treatment
of irritability associated with autism spectrum disorder. Expert Opin Emerg Drugs.
2024;29(1):45–56.
119. Pourmand A, AlRemeithi R, Kartiko S, etal. Evaluation of phenobarbital based approach in
treating patient with alcohol withdrawal syndrome: a systematic review and meta-analysis.
Am J Emerg Med. 2023;69:65–75.
120. Shah P, Stegner-Smith KL, Rachid M, etal. Front-loaded versus low-intermittent phenobarbital dosing for benzodiazepine-resistant severe alcohol withdrawal syndrome. J Med Toxicol.
2022;18(3):198–204.
121. Pham C, Goldenberg-Sandau A, Sensenig R, et al. Phenobarbital for the management
of alcohol withdrawal syndrome in critically ill, surgical-trauma patients. J Surg Res.
2023;283:965–72.
122. Terasaki D, Kulick B, Calcaterra S, etal. Phenobarbital for alcohol withdrawal in the context
of the opioid epidemic: a neglected caveat. Addiction. 2023;118(7):1198–200.
123. Handley R, Stewart AS. Mysoline; a new drug in the treatment of epilepsy. Lancet.
1952;1(6711):742–4.
124. Goldin S.Toxic effects of primidone. Lancet. 1954;266(6802):102–3.
125. Nathan PW. Primidone in the treatment of non-idiopathic epilepsy. Lancet.
1954;266(6801):21–3.
126. Scarinci V. [Pharmacology of mysoline (primidone)]. Arch Ital Sci Farmacol. 1955;5(1):10–5.
127. Lopez-Gomez M, Ramirez-Bermudez J, Campillo C, et al. Primidone is associated with
interictal depression in patients with epilepsy. Epilepsy Behav. 2005;6(3):413–6.
128. Lenka A, Louis ED.Primidone intolerance in essential tremor: is it more than just age?
Tremor Other Hyperkinet Mov (N Y). 2021;11:57.
129. Steve TA, Gross DW. Alcohol-responsive epilepsia partialis continua. Epileptic Disord.
2014;16(1):107–11.
130. Wang J, Huang P, Song Z.Comparison of the relapse rates in seizure-free patients in whom
antiepileptic therapy was discontinued and those in whom the therapy was continued: a metaanalysis. Epilepsy Behav. 2019;101(Pt A):106577.
131. Demchenko IT, Zhilyaev SY, Moskvin AN, et al. Antiepileptic drugs prevent seizures in
hyperbaric oxygen: a novel model of epileptiform activity. Brain Res. 2017;1657:347–54.
132. Canisius T, Soons J, Verschuure P, et al. Therapeutic drug monitoring of anti-epileptic
drugs– a clinical verication of volumetric absorptive micro sampling. Clin Chem Lab Med.
2020;58(5):828–35.
133. Ghosh D, Brar H, Lhamu U, etal. A series of 211 children with probable essential tremor.
Mov Disord Clin Pract. 2017;4(2):231–6.
134. Castonguay CE, Liao C, Khayachi A, et al. Transcriptomic effects of propranolol and
primidone converge on molecular pathways relevant to essential tremor. NPJ Genom Med.
2022;7(1):46.
135. Tensini TS, Von Glehn CQC, Bettinotti MP, etal. Cutaneous adverse reactions associated
with antiseizure medication: clinical characteristics and implications in epilepsy treatment.
Epileptic Disord. 2021;23(3):466–75.
136. Krügel U, Straub I, Beckmann H, etal. Primidone inhibits TRPM3 and attenuates thermal
nociception invivo. Pain. 2017;158(5):856–67.
137. Arjunan V, Santhanam R, Subramanian S, etal. Primidone--an antiepileptic drug--characterisation by quantum chemical and spectroscopic (FTIR, FT-Raman, 1H, 13C NMR and
UV-Visible) investigations. Spectrochim Acta A Mol Biomol Spectrosc. 2013;109:282–97.
138. Riebeling T, Jamal K, Wilson R, etal. Primidone blocks RIPK1-driven cell death and inammation. Cell Death Differ. 2021;28(5):1610–26.
139. Nida A, Alston J, Schweinfurth J. Primidone therapy for essential vocal tremor. JAMA
Otolaryngol Head Neck Surg. 2016;142(2):117–21.
293
294
140. Ashikawa H, Mogi H, Honda T, etal. Benecial effects of primidone in Niemann-Pick disease type C (NPC)-model cells and mice: reduction of unesteried cholesterol levels in cells
and extension of lifespan in mice. Eur J Pharmacol. 2021;896:173907.
141. Burton B.On the propyl derivatives and decomposition products of ethyl acetoacetate. Am
Chem J. 1881;3:385–95.
142. Barnes SE, Bower BD.Sodium valproate in the treatment of intractable childhood epilepsy.
Dev Med Child Neurol. 1975;17(2):175–81.
143. Bohlen N, Hertl M. [Adverse effects of anti-epileptic drugs]. Dtsch Med Wochenschr.
1975;100(38):1904–6.
144. Shnayder NA, Grechkina VV, Khasanova AK, etal. Therapeutic and toxic effects of valproic
acid metabolites. Metabolites. 2023;13(1):134.
145. Marson A, Burnside G, Appleton R, etal. The SANAD II study of the effectiveness and costeffectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled
trial. Lancet. 2021;397(10282):1375–86.
146. Hochbaum M, Kienitz R, Rosenow F, etal. Trends in antiseizure medication prescription
patterns among all adults, women, and older adults with epilepsy: a German longitudinal
analysis from 2008 to 2020. Epilepsy Behav. 2022;130:108666.
147. Yu L, Zhu W, Zhu X, et al. Anti-seizure medication prescription in adult outpatients with
epilepsy in China, 2013-2018. Front Neurol. 2021;12:649589.
148. Clavenna A, Campi R, Putignano D, et al. Changes in antiepileptic drug prescriptions
over a decade in childbearing women in Lombardy region, Italy. Br J Clin Pharmacol.
2022;88(3):1152–8.
149. Kikuchi D, Obara T, Miura R, et al. Trends in the prescription of anti-seizure medicines for pregnant women outpatients with epilepsy during 2016-2020in Japan. Seizure.
2022;98:101–4.
150. Romoli M, Mazzocchetti P, D’Alonzo R, etal. Valproic acid and epilepsy: from molecular
mechanisms to clinical evidences. Curr Neuropharmacol. 2019;17(10):926–46.
151. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35
years of clinical experience. CNS Drugs. 2002;16(10):695–714.
152. Young MR, Bisaccia EK, Romantseva L, etal. Valproic acid serum concentration and incidence of toxicity in pediatric patients. J Child Neurol. 2022;37(6):461–70.
153. Lin K, Cao VFS, Au C, etal. Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review. Clin Pharmacokinet. 2022;61(10):1345–63.
154. El Orche A, Cheikh A, Johnson JB, etal. A novel approach for therapeutic drug monitoring
of valproic acid using FT-IR spectroscopy and nonlinear support vector regression. J AOAC
Int. 2023;106(4):1070–6.
155. Namera A, Uekusa K, Saito T, etal. A method for determining valproic acid in human whole
blood and urine via gas chromatography-mass spectrometry and small-scale inter-laboratory
trial. Leg Med (Tokyo). 2022;59:102133.
156. Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol.
2016;15(2):210–8.
157. Gong X, Liu Y, Liu X, et al. Analysis of gut microbiota in patients with epilepsy treated
with valproate: results from a three months observational prospective cohort study. Microb
Pathog. 2022;162:105340.
158. Kandratavicius L, Balista PA, Lopes-Aguiar C, etal. Animal models of epilepsy: use and
limitations. Neuropsychiatr Dis Treat. 2014;10:1693–705.
159. Luszczki JJ, Trojnar MK, Ratnaraj N, etal. Interactions of stiripentol with clobazam and
valproate in the mouse maximal electroshock-induced seizure model. Epilepsy Res.
2010;90(3):188–98.
160. Srivastava AK, White HS.Carbamazepine, but not valproate, displays pharmacoresistance in
lamotrigine-resistant amygdala kindled rats. Epilepsy Res. 2013;104(1–2):26–34.
W. Jing et al.
2 Antiseizure Medications
161. Langer M, Brandt C, Zellinger C, etal. Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology. 2011;61(5–6):1033–47.
162. Sgobio C, Ghiglieri V, Costa C, etal. Hippocampal synaptic plasticity, memory, and epilepsy:
effects of long-term valproic acid treatment. Biol Psychiatry. 2010;67(6):567–74.
163. Can Kantarci B, Sanli A, Gavas S, etal. Effects of in utero exposure to valproate or levetiracetam on the seizures and newborn histopathology of genetic absence epilepsy rats. Neurosci
Lett. 2022;776:136574.
164. Ayala-Guerrero F, Castro-Domínguez D, Mateos-Salgado EL, etal. Effect of valproate on
sleep patterns disturbed by epilepsy. Physiol Behav. 2023;259:114054.
165. Wang W, Wu J, Li S, etal. Sodium valproate for epilepsy in rural China: an efcacy and
safety assessment in primary care. Epilepsy Res. 2012;102(3):201–5.
166. Huang DH, Zheng JO, Chen J, etal. Treatment gaps of epilepsy and retention rates of sodium
valproate in rural Guangxi, China. Genet Mol Res. 2014;13(3):6202–12.
167. Hu Y, Huang X, Shen D, etal. Outcomes of sustained-release formulation of valproate and
topiramate monotherapy in patients with epilepsy: a multi-centre, cohort study. PLoS One.
2012;7(12):e47982.
168. Marques VD, Hackbart BA, Guilhoto LM, etal. Minimum effective sodium valproate dose in
genetic generalized epilepsies. Seizure. 2023;108:53–9.
169. Steinbart D, Gaus V, Kowski AB, etal. Valproic acid use in fertile women with genetic generalized epilepsies. Acta Neurol Scand. 2021;144(3):288–95.
170. Mermi Dibek D, Öztura İ, Baklan B.Our reasons for converting to valproic acid treatment in
female patients with genetic generalized epilepsy: a retrospective, single-centre study. Neurol
Sci. 2022;43(1):517–23.
171. Kiiski R, Basnyat P, Raitanen J, etal. Treatment outcomes in women with idiopathic generalized epilepsy. Acta Neurol Scand. 2022;145(4):423–33.
172. Baheti N, Rathore C, Bansal AR, etal. Treatment outcomes in drug resistant juvenile myoclonic epilepsy: valproate resistance may not be the end of the road. Seizure. 2021;92:112–7.
173. Kılıç B, Serdaroğlu E, Polat BG, etal. Trends in the choice of antiseizure medications in
juvenile myoclonic epilepsy: a retrospective multi-center study from Turkey between 2010
and 2020. Seizure. 2022;99:48–53.
174. Moon JU, Lee JY, Kim KY, etal. Comparative analysis of background EEG activity in juvenile myoclonic epilepsy during valproic acid treatment: a standardized, low-resolution, brain
electromagnetic tomography (sLORETA) study. BMC Neurol. 2022;22(1):48.
175. Zöllner JP, Strzelczyk A, Rosenow F, etal. Valproate but not levetiracetam slows the EEG
alpha peak frequency– a pharmaco-EEG study. Clin Neurophysiol. 2021;132(6):1203–8.
176. Ozyurek H, Bayrak I, Yayici Koken O, etal. Effect of chronic valproic acid use on anterior
cerebral blood ow of children with idiopathic generalized epilepsy. Acta Neurol Taiwanica.
2022;31(2):72–6.
177. Operto FF, Pastorino GMG, Di Bonaventura C, etal. Effects of antiseizure monotherapy on
visuospatial memory in pediatric age. Eur J Paediatr Neurol. 2021;32:106–14.
178. Zaccara G, Lattanzi S, Brigo F.Which treatment strategy in patients with epilepsy with focal
seizures uncontrolled by the rst anti-seizure medication? Epilepsy Behav. 2021;121(Pt
A):108031.
179. Zhu Y, Yang J, Zhu X.Combined effects of levetiracetam and sodium valproate on paediatric
patients with epilepsy: a systematic review and meta-analysis. Seizure. 2022;95:17–25.
180. Sharshar T, Porcher R, Asfar P, etal. Valproic acid as adjuvant treatment for convulsive status
epilepticus: a randomised clinical trial. Crit Care. 2023;27(1):8.
181. Liampas I, Siokas V, Brotis A, etal. Intravenous sodium valproate in status epilepticus:
review and meta-analysis. Int J Neurosci. 2021;131(1):70–84.
182. Kamitaki BK, Minacapelli CD, Zhang P, etal. Drug-induced liver injury associated with
antiseizure medications from the FDA Adverse Event Reporting System (FAERS). Epilepsy
Behav. 2021;117:107832.
295
296
183. Loser V, Novy J, Beuchat I, etal. Acute valproate-induced encephalopathy in status epilepticus: a registry-based assessment. CNS Drugs. 2023;37(8):725–31.
184. Bui E.Women’s issues in epilepsy. Continuum (Minneap Minn). 2022;28(2):399–427.
185. Eriksson SH, Tittensor P, Sisodiya SM.National compliance with UK wide guidelines for
usage of valproate in women of childbearing potential. Seizure. 2022;98:8–12.
186. Spoendlin J, Blozik E, Graber S, etal. Use of valproate in pregnancy and in women of childbearing age between 2014 and 2018in Switzerland: a retrospective analysis of Swiss healthcare claims data. Swiss Med Wkly. 2021;151:w20386.
187. Atalar A, Şirin NG, Bebek N, etal. Predictors of successful valproate withdrawal in women
with epilepsy. Epilepsy Behav. 2021;119:107980.
188. Roberti R, Rocca M, Iannone LF, etal. Status epilepticus in pregnancy: a literature review
and a protocol proposal. Expert Rev Neurother. 2022;22(4):301–12.
189. Borowicz-Reutt KK.Effects of antiarrhythmic drugs on antiepileptic drug action-a critical
review of experimental ndings. Int J Mol Sci. 2022;23(5):2891.
190. Giustozzi M, Mazzetti M, Paciaroni M, etal. Concomitant use of direct oral anticoagulants
and antiepileptic drugs: a prospective cohort study in patients with atrial brillation. Clin
Drug Investig. 2021;41(1):43–51.
191. Cherian A, Shetty SC, Divya KP, etal. Weekly methotrexate may reduce valproate levels
causing relapse of genetic generalized epilepsy. Epilepsy Behav Rep. 2021;16:100457.
192. Li Z, Gao W, Liu G, et al. Interaction between valproic acid and carbapenems: decreased
plasma concentration of valproic acid and liver injury. Ann Palliat Med. 2021;10(5):5417–24.
193. Chen IL, Lee CH, Hsiao SC, et al. Interactions between carbapenems and valproic acid
among the patients in the intensive care units. J Crit Care. 2021;62:151–6.
194. Cunningham D, Clark K, Lord K.Treatment of valproic acid overdose with meropenem in an
epileptic patient. Am J Emerg Med. 2022;53:284.e1–3.
195. Yang X, Jiang Z, Jiang Y, et al. Determination of valproic acid and its six metabolites in
human serum using LC-MS/MS and application to interaction with carbapenems in epileptic
patients. Biomed Chromatogr. 2023;37(3):e5572.
196. Müller A, von Hofen-Hohloch J, Awissus C, etal. Does diabetes mellitus affect the safety
prole of valproic acid for the treatment of status epilepticus? A retrospective cohort study.
Neurol Res Pract. 2022;4(1):52.
197. Snoeijen-Schouwenaars FM, Young C, Rowe C, etal. People with epilepsy and intellectual
disability: more than a sum of two conditions. Epilepsy Behav. 2021;124:108355.
198. Kessing LV, Ziersen SC, Gerds T, et al. Response to lithium and anticonvulsants among
patients with bipolar disorder with and without comorbid epilepsy– a nation-wide populationbased longitudinal study. J Affect Disord. 2022;308:369–74.
199. Pisani F, Rosa Pisani L, Barbieri MA, etal. Optimization of therapy in patients with epilepsy
and psychiatric comorbidities: key points. Curr Neuropharmacol. 2023;21(8):1755–66.
200. Hsieh TC, Lin CC, Wu LS. Long-term use of valproic acid reduced mortality in bipolar
disorder patients in a Taiwanese population: an association analysis using the national health
insurance research database (NHIRD). J Psychiatr Res. 2022;149:339–43.
201. Xie T, Li R, Long X, etal. Magnetic resonance imaging features of hippocampus and mechanism of neurocognitive dysfunction for antiepileptic drugs in treatment of depression rats.
Bioengineered. 2022;13(3):4646–57.
202. Cuartas CF, Davis M.Valproic acid in the management of delirium. Am J Hosp Palliat Care.
2022;39(5):562–9.
203. Olivola M, Civardi S, Damiani S, etal. Effectiveness and safety of intravenous valproate in
agitation: a systematic review. Psychopharmacology. 2022;239(2):339–50.
204. Gao X, Zeb S, He YY, etal. Valproic acid inhibits glial scar formation after ischemic stroke.
Pharmacology. 2022;107(5–6):263–80.
205. Lee H, Hwang YJ, Park JH, etal. Valproic acid decreases vascular smooth muscle cell proliferation via protein phosphatase 2A-mediated p70 S6 kinase inhibition. Biochem Biophys
Res Commun. 2022;606:94–9.
W. Jing et al.
2 Antiseizure Medications
206. Wakam GK, Biesterveld BE, Pai MP, et al. Administration of valproic acid in clinically
approved dose improves neurologic recovery and decreases brain lesion size in swine
subjected to hemorrhagic shock and traumatic brain injury. J Trauma Acute Care Surg.
2021;90(2):346–52.
207. Bhatti UF, Remmer H, Williams AM, etal. Assessment of the cytoprotective effects of highdose valproic acid compared to a clinically used lower dose. J Surg Res. 2021;266:125–41.
208. Bhatti UF, Karnovsky A, Dennahy IS, etal. Pharmacologic modulation of brain metabolism by valproic acid can induce a neuroprotective environment. J Trauma Acute Care Surg.
2021;90(3):507–14.
209. Demirci H, Kuzucu P, Seymen CM, etal. The effect of antiepileptic drugs on re- myelinization
of axons: phenytoin, levetiracetam, carbamazepine, and valproic acid, used following traumatic brain injury. Clin Neurol Neurosurg. 2021;209:106911.
210. Biesterveld BE, Siddiqui AZ, O’Connell RL, etal. Valproic acid protects against acute kidney
injury in hemorrhage and trauma. J Surg Res. 2021;266:222–9.
211. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, etal. Valproic acid as epigenetic
cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat
Rev. 2008;34(3):206–22.
212. Chen JH, Zheng YL, Xu CQ, etal. Valproic acid (VPA) enhances cisplatin sensitivity of nonsmall cell lung cancer cells via HDAC2 mediated down regulation of ABCA1. Biol Chem.
2017;398(7):785–92.
213. Happold C, Gorlia T, Chinot O, etal. Does valproic acid or levetiracetam improve survival
in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol. 2016;34(7):731–9.
214. Memezawa S, Sato T, Ochiai A, etal. The antiepileptic valproic acid ameliorates CharcotMarie- Tooth 2W (CMT2W) disease-associated HARS1 mutation-induced inhibition of neuronal cell morphological differentiation through c-Jun N-terminal kinase. Neurochem Res.
2022;47(9):2684–702.
215. Kurishima A, Hayashi M, Shimozato R, etal. Successful treatment of symptomatic epilepsy
with oral valproic acid and levetiracetam in a patient with short-bowel syndrome. Intern Med.
2022;61(9):1457–61.
216. Santos DS, Rocha MA, Mello MLS.Epigenetic studies in insects and the valproic acid perspective. Braz J Biol. 2022;84:e256045.
217. Saiz ML, DeDiego ML, López-García D, etal. Epigenetic targeting of the ACE2 and NRP1
viral receptors limits SARS-CoV-2 infectivity. Clin Epigenetics. 2021;13(1):187.
218. Farazdaghi M, Razavizadegan SMA, Moghimi M, etal. Efcacy of valproic acid against
coronavirus disease 2019 infection or severity: a pilot study. Clin Neuropharmacol.
2022;45(6):175–6.
219. Fu M, Zhu Y, Zhang J, et al. MicroRNA-221-3p suppresses the microglia activation and
seizures by inhibiting of HIF-1α in valproic acid-resistant epilepsy. Front Pharmacol.
2021;12:714556.
220. Wang Y, Li Y, Wang G, etal. Overexpression of Homer1b/c induces valproic acid resistance
in epilepsy. CNS Neurosci Ther. 2023;29(1):331–43.
221. Romoli M, Costa C, Siliquini S, etal. Antiepileptic drugs in migraine and epilepsy: who is at
increased risk of adverse events? Cephalalgia. 2018;38(2):274–82.
222. Wartman C, VandenBerg A. Valproate: not all boxed warnings are created equal. Ann
Pharmacother. 2022;56(12):1349–55.
223. Ezhilarasan D, Mani U.Valproic acid induced liver injury: an insight into molecular toxicological mechanism. Environ Toxicol Pharmacol. 2022;95:103967.
224. Meseguer ES, Elizalde MU, Borobia AM, etal. Valproic acid-induced liver injury: a casecontrol study from a prospective pharmacovigilance program in a tertiary hospital. J Clin
Med. 2021;10(6):1153.
225. Mei X, Wu HC, Ruan M, etal. Acute liver failure with thrombotic microangiopathy due to
sodium valproate toxicity: a case report. World J Clin Cases. 2021;9(17):4310–7.
297
298
226. Gheena S, Ezhilarasan D, Shree Harini K, et al. Syringic acid and silymarin concurrent
administration inhibits sodium valproate-induced liver injury in rats. Environ Toxicol.
2022;37(9):2143–52.
227. George LJ, Singh P, Aneja S, etal. Insulin resistance in children on sodium valproate– a
hospital based cross-sectional study in Indian children. Trop Doct. 2023;53(1):91–6.
228. Sun JW, Young JG, Sarvet AL, etal. Comparison of rates of type 2 diabetes in adults and children treated with anticonvulsant mood stabilizers. JAMA Netw Open. 2022;5(4):e226484.
229. Yaryari AM, Mazdeh M, Mohammadi M, etal. Evaluation of serum levels of asprosin and
other metabolic proles in patients with idiopathic tonic-clonic generalized epilepsy on treatment with valproic acid. Eur J Clin Pharmacol. 2022;78(3):393–403.
230. Yan L, Yang K, Wang S, et al. PXR-mediated expression of FABP4 promotes valproateinduced lipid accumulation in HepG2 cells. Toxicol Lett. 2021;346:47–56.
231. Guo HL, Dong N, Chen F, etal. Effect of long-term valproic acid therapy on lipid proles
in paediatric patients with epilepsy: a meta-analysis. Epileptic Disord. 2022;24(5):822–30.
232. Jutrić D, Đikić D, Boroš A, etal. Effects of naringin and valproate interaction on liver
steatosis and dyslipidaemia parameters in male C57BL6 mice. Arh Hig Rada Toksikol.
2022;73(1):71–82.
233. Conei D, Rojas M, Santamaría L, etal. Valproic acid during pregnancy decrease the number
of spermatogenic cells and testicular volume in the offspring of mice: stereological quantication. Histol Histopathol. 2021;36(11):1189–98.
234. Alsemeh AE, Ahmed MM, Fawzy A, etal. Vitamin E rescues valproic acid-induced testicular
injury in rats: role of autophagy. Life Sci. 2022;296:120434.
235. Guo Y, Chen L, Wu D, etal. A comparative study of the effects of valproate and oxcarbazepine on sexual function, sperm quality, and sex hormones in males with epilepsy. Biomed Res
Int. 2021;2021:6624101.
236. Rochtus AM, Herijgers D, Jansen K, etal. Antiseizure medications and thyroid hormone
homeostasis: literature review and practical recommendations. Epilepsia. 2022;63(2):259–70.
237. Comert E, Celebi U, Piri Cinar B, etal. Thyroid functions as a parameter in monitoring of
antiepileptic drugs. Neurol Res. 2022;44(7):614–21.
238. Ilia TS, Dragoumi P, Papanikolopoulou S, etal. Is the prevalence of thyroid disease higher in
children receiving antiepileptic medication? A systematic review and meta-analysis. Seizure.
2022;94:117–25.
239. Saito M, Takizawa T, Miyaoka H.Factors associated with blood carnitine levels in adult epilepsy patients with chronic valproic acid therapy. Epilepsy Res. 2021;175:106697.
240. Okumura A, Takagi M, Numoto S, etal. Effects of l-carnitine supplementation in patients
with childhood-onset epilepsy prescribed valproate. Epilepsy Behav. 2021;122:108220.
241. Christensen J, Trabjerg BB, Sun Y, etal. Prenatal exposure to valproate and risk of congenital malformations-could we have known earlier?-a population-based cohort study. Epilepsia.
2021;62(12):2981–93.
242. Piorczynski TB, Larsen MW, Lee SJ, etal. NRF2 activation protects against valproic acidinduced disruption of neurogenesis in P19 cells. Differentiation. 2022;123:18–29.
243. Steele JW, Lin YL, Chen N, etal. Embryonic hypotaurine levels contribute to strain- dependent
susceptibility in mouse models of valproate-induced neural tube defects. Front Cell Dev Biol.
2022;10:832492.
244. Brotzmann K, Wolterbeek A, Kroese D, et al. Neurotoxic effects in zebrash embryos
by valproic acid and nine of its analogues: the sh-mouse connection? Arch Toxicol.
2021;95(2):641–57.
245. Muhsen M, Youngs J, Riu A, etal. Folic acid supplementation rescues valproic acid-induced
developmental neurotoxicity and behavioral alterations in zebrash embryos. Epilepsia.
2021;62(7):1689–700.
246. Meng Q, Zhang W, Wang X, etal. Human forebrain organoids reveal connections between
valproic acid exposure and autism risk. Transl Psychiatry. 2022;12(1):130.
W. Jing et al.
2 Antiseizure Medications
247. Liu Z, Wang J, Xu Q, etal. Vitamin A supplementation ameliorates prenatal valproic acidinduced autism-like behaviors in rats. Neurotoxicology. 2022;91:155–65.
248. Honybun E, Thwaites R, Malpas CB, etal. Prenatal valproate exposure and adverse neurodevelopmental outcomes: does sex matter? Epilepsia. 2021;62(3):709–19.
249. Bjørk MH, Zoega H, Leinonen MK, etal. Association of prenatal exposure to antiseizure
medication with risk of autism and intellectual disability. JAMA Neurol. 2022;79(7):672–81.
250. Feleke R, Jazayeri D, Abouzeid M, etal. Integrative genomics reveals pathogenic mediator of
valproate-induced neurodevelopmental disability. Brain. 2022;145(11):3832–42.
251. Kowalski TW, Lord VO, Sgarioni E, etal. Transcriptome meta-analysis of valproic acid exposure in human embryonic stem cells. Eur Neuropsychopharmacol. 2022;60:76–88.
252. Hosseini H, Shae M, Shakiba A, etal. Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey. Psychopharmacology. 2023;240(1):149–56.
253. Kwack DW, Kim DW.Risk factors of hyperammonemia in epilepsy patients with valproic
acid therapy. Clin Neurol Neurosurg. 2023;233:107962.
254. Pagali S, Edquist C, O’Rourke N.Managing valproic acid toxicity-related hyperammonaemia: an unpredicted course. BMJ Case Rep. 2021;14(4):e241547.
255. Patel J, Berezowski I, Mazer-Amirshahi M, etal. Valproic acid overdose: case report and
literature review. J Emerg Med. 2022;63(5):651–5.
256. Lan L, Zhao X, Jian S, etal. Investigation of the risk of valproic acid-induced tremor: clinical,
neuroimaging, and genetic factors. Psychopharmacology. 2022;239(1):173–84.
257. Baizabal-Carvallo JF, Alonso-Juarez M.Valproate-induced rest tremor and parkinsonism.
Acta Neurol Belg. 2021;121(2):515–9.
258. Rissardo JP, Caprara ALF, Durante Í. Valproate-associated movement disorder: a literature
review. Prague Med Rep. 2021;122(3):140–80.
259. de Oliveira-Costa GVC, Machado Torres C, Ávila Duarte J, et al. Valproate-induced
reversible hemichoreoathetosis in a patient with Rasmussen encephalitis. Neurology.
2022;98(21):894–5.
260. Yıldız A, Vardı N, Parlakpınar H, etal. Effects of low- and high-dose valproic acid and
lamotrigine on the heart in female rats. Cardiovasc Toxicol. 2022;22(4):326–40.
261. Liang D, Gardella E, Kragholm K, etal. The relationship between valproate and lamotrigine/
levetiracetam use and prognosis in patients with epilepsy and heart failure: a Danish registerbased study. J Card Fail. 2022;28(4):630–8.
262. Anguissola G, Leu D, Simonetti GD, etal. Kidney tubular injury induced by valproic acid:
systematic literature review. Pediatr Nephrol. 2023;38(6):1725–31.
263. Bayrak BB, Yilmaz S, Hacihasanoglu Cakmak N, etal. The effects of edaravone, a freeradical scavenger in lung injury induced by valproic acid demonstrated via different biochemical parameters. J Biochem Mol Toxicol. 2021;35(9):e22847.
264. Bischof MCM, Stadelmann MIE, Janett S, etal. Valproic acid-associated acute pancreatitis:
systematic literature review. J Clin Med. 2023;12(18):6044.
265. Gallo C, Bonvento G, Zagotto G, etal. Gingival overgrowth induced by anticonvulsant drugs:
a cross-sectional study on epileptic patients. J Periodontal Res. 2021;56(2):363–9.
266. Heidemann J, Schmitz B, Kostev K.Association between antiseizure medication use and risk
of urinary tract infection: a case-control study. Epilepsy Behav. 2021;115:107502.
267. Post DS, van der Veer A, Schijns O, et al. Assessment of need for hemostatic evaluation in patients taking valproic acid: a retrospective cross-sectional study. PLoS One.
2022;17(2):e0264351.
268. Riahi-Zanjani B, Delirrad M, Fazeli-Bakhtiyari R, et al. Hematological consequences of
valproic acid in pediatric patients: a systematic review with a mechanistic approach. CNS
Neurol Disord Drug Targets. 2022;21(4):316–25.
269. Papadopoulou E, Saroglou M, Ismailos G, etal. Pearls for the diagnosis and possible pathophysiological mechanisms of valproic acid-induced lupus erythematosus: a literature review.
Lupus. 2022;31(6):650–8.
299